Provided herein are compounds of formula (I) having activity on a receptor protein tyrosine kinase, wherein R.sup.1, R.sup.2, R.sup.3, A, Q, Z, X and W are set forth in the description, as well as solvates, hydrates, tautomers or pharmaceutically acceptable salts thereof.

##STR00001##

The present invention relates to a heterocyclic sulfoximine compound represented by formula (I), and racemates, enantiomers, pharmaceutically acceptable salts or solvates thereof. Also disclosed herein are an intermediate compound for synthesizing the compound, a preparation method therefor, and a pharmaceutical composition comprising the compound and use thereof. The compound is RET, RET mutant, or RET fusion protein inhibitor, capable of treating diseases caused by abnormal activity of RET, RET mutant, or RET fusion protein, for example, tumors.

A new set of bench-stable fluoroalkylphosphines that directly convert C—H bonds in pyridine building blocks, drug-like fragments, and pharmaceuticals, into fluoroalkyl derivatives. No pre-installed functional groups or directing motifs are required. The reaction tolerates a variety of sterically and electronically distinct pyridines and is exclusively selective for the 4-position in most cases. The reaction proceeds via initial phosphonium salt formation followed by sp.sup.2-sp.sup.3 phosphorus ligand-coupling, an underdeveloped manifold for C—C bond formation.

The present disclosure relates to an aromatic amine derivative represented by general formula (I). ##STR00001## The aromatic amine derivative has fluorescence emission at a short light emission wavelength, and the light-emission spectrum of the aromatic amine derivative has a narrow half-peak width, and accordingly, the material has deep-blue fluorescence emission and has a very-high light emission efficiency. An organic electroluminescent component prepared by using the aromatic amine derivative has deep-blue color coordinates, a high light emission efficiency and a long life-span.

Provided herein, inter alia, are compound and methods of treating cancer by inhibiting HDAC8.

Provided herein, inter alia, are compound and methods of treating cancer by inhibiting HDAC8.

The invention relates to compounds and methods of using said compounds, as well as pharmaceutical compositions containing such compounds, for treating diseases and conditions mediated by TEAD, such as cancer.

The invention relates to compounds and methods of using said compounds, as well as pharmaceutical compositions containing such compounds, for treating diseases and conditions mediated by TEAD, such as cancer.

The present invention concerns novel pyridin-2(1H)one derivatives, their process of preparation and their use in therapeutics, in particular as agents for treating and/or preventing pain.

The present invention concerns novel pyridin-2(1H)one derivatives, their process of preparation and their use in therapeutics, in particular as agents for treating and/or preventing pain.